<DOC>
	<DOCNO>NCT00036439</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness safety infliximab ( Remicade ) patient Ulcerative Colitis .</brief_summary>
	<brief_title>A Safety Efficacy Study Infliximab ( Remicade ) Patients With Active Ulcerative Colitis</brief_title>
	<detailed_description>This study design investigate safety effectiveness medication call infliximab ( active drug ( REMICADEÂ® ) adult patient active ulcerative colitis . The purpose study see symptom ulcerative colitis lessen medication , infliximab , dose need safely . Patients receive infusion either 5mg/kg , 10 mg/kg placebo week 0 , 2 , 6 , every 8 week thereafter week 46 3 year . Safety evaluation perform specify interval throughout study consist laboratory test , vital sign ( blood pressure ) , physical examination occurrence severity adverse event well study specific procedure . Patients receive infusion either 5mg/kg , 10 mg/kg placebo week 0 , 2 , 6 , every 8 week thereafter week 46 3 year .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Patients ulcerative colitis least 3 month ' duration screen Patients ulcerative colitis confirm biopsy take screen Patients must active colitis confirm screen sigmoidoscopy Patients must active disease . Patients must likely require surgical removal part colon within 12 week begin study Patients must require , require within 2 month prior begin study , surgery active gastrointestinal bleeding , peritonitis , intestinal obstruction , intraabdominal pancreatic abscess require surgical drainage</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>ulcerative colitis</keyword>
	<keyword>infliximab</keyword>
	<keyword>Remicade</keyword>
	<keyword>infusion</keyword>
</DOC>